May 26, 2017 4:29 PM ET

Biotechnology

Company Overview of Genocea Biosciences, Inc.

Company Overview

Genocea Biosciences, Inc., a biopharmaceutical company, engages in developing T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. The company uses AnTigen Lead Acquisition System (ATLAS), its proprietary discovery platform to build a pipeline of immunotherapies and its first neoantigen cancer vaccine. Its lead product candidate is GEN-003, a therapeutic vaccine or immunotherapy that is in Phase 2 trial for the treatment of genital herpes infections. The company is also developing GEN-009, which is in pre-clinical stage for the treatment of immuno-oncology-neoantigen; and GEN-007 that is in research stage for the treatment of Epstein-Barr virus. Genocea Biosc...

100 Acorn Park Drive

5th Floor

Cambridge, MA 02140

United States

Founded in 2006

98 Employees

Phone:

617-876-8191

Fax:

617-876-8192

Key Executives for Genocea Biosciences, Inc.

Chief Executive Officer, President and Director
Age: 47
Total Annual Compensation: $455.5K
Chief Financial Officer and Secretary
Age: 41
Total Annual Compensation: $367.4K
Chief Medical Officer
Age: 64
Total Annual Compensation: $390.1K
Compensation as of Fiscal Year 2016.

Genocea Biosciences, Inc. Key Developments

Genocea Biosciences, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017

Genocea Biosciences, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2017. For the quarter, the company reported loss from operations of $13,376,000 against $9,429,000 a year ago. Net loss was $13,735,000 or $0.48 per basic and diluted share against $9,751,000 or $0.35 per basic and diluted share a year ago.

Genocea Biosciences, Inc., Q1 2017 Earnings Call, May 04, 2017

Genocea Biosciences, Inc., Q1 2017 Earnings Call, May 04, 2017

Genocea Biosciences, Inc. Announces Executive Changes

On April 14, 2017, Genocea Biosciences, Inc. notified NASDAQ that Dr. Stephen Hoffman had resigned from the Board of Directors of the company effective April 11, 2017. On April 14, 2017, the Board appointed Dr. Howard Mayer to serve as a member of the Compensation Committee.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Genocea Biosciences, Inc., please visit www.genocea.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.